Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?

Clicks: 296
ID: 95448
2016
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In the last years, several metal-based compounds have been designed and biologically investigated worldwide in order to obtain chemotherapeutics with a better toxicological profile and comparable or higher antiblastic activity than the clinically-established platinum-based drugs. In this context, researchers have addressed their attention to alternative nonplatinum derivatives able to maximize the anticancer activity of the new drugs and to minimize the side effects. Among them, a number of ruthenium complexes have been developed, including the compounds NAMI-A and KP1019, now in clinical trials. Here, we report the results collected so far for a particular class of ruthenium complexes - the ruthenium(II/III)-dithiocarbamates - which proved more potent than cisplatin in vitro, even at nanomolar concentrations, against a wide panel of human tumor cell lines.
Reference Key
nardon2016isfuture Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nardon, Chiara;Brustolin, Leonardo;Fregona, Dolores;
Journal Future medicinal chemistry
Year 2016
DOI
10.4155/fmc.15.175
URL
Keywords
Cancer ruthenium cisplatin metal complexes dithiocarbamate nami-a chemoprotectant heteroleptic homoleptic redox reaction

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.